GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin

Bayer

Status: Completed

Conditions: Diabetes Mellitus

Treatments: Drug: Acarbose (Glucobay, BAYG5421)

Study type: Observational

Funder types: Industry

Identifiers

NCT01248481

GB1010KR (Other Identifier)

15316

Details and patient eligibility

About

To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.

Enrollment: 539 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent
• Age ≥ 18 years
• Diagnosed of type 2 diabetes for at least 6 months prior to enrollment
• Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months
• HbA1C≥7.5 and ≤10.0%

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information

Trial design

539 participants in 1 patient group

Group 1

Treatment:

Drug: Acarbose (Glucobay, BAYG5421)